Experts lend a hand in Unigen strategy

Plant extract supplier Unigen Pharmaceuticals has formed an advisory board of health experts to review the latest research, existing products and discoveries to help it plan future developments.

Plant extract supplier Unigen Pharmaceuticals has formed an advisory board of health experts to review the latest research, existing products and discoveries to help it plan future developments.

The board, which held its first meeting last month, is chaired by Marcus Laux, a licensed naturopathic physician and an Affiliate faculty member at Bastyr University in Seattle, Washington. Other members include Donald K. Layman, professor of Nutrition at the University of Illinois at Urbana-Champaign and former associate editor of the Journal of Nutrition, Leonard Makowka, a clinical surgeon, transplantation specialist and medical researcher,Glynnis Mileikowsky, senior vice president of business expansion for Phillips Health and Adam Morgan, formerly vice president of New Business Development at Rexall Sundown.

Derek Hall, president and CEO of Unigen, said the board will help the business "achieve our vision and strategic plan. In so doing, Unigen will remain at the forefront of science and technology in developing innovative, natural products that address today's and tomorrow's most important health concerns".

Unigen has recently introduced DiAfin, a non-stimulant botanical product known to aid in weight loss, the extract Lasoperin, a cognition enhancing product, and Soliprin, which promotes skin protection, healing and repair. The company is a subsidiary of Univera.